Compare Crispr Therapeutics AG (CRSP) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Yum! Brands, Inc. — how do they compare? Crispr Therapeutics AG trades at $53.65 (market cap $4.88B), while Yum! Brands, Inc. trades at $144.94 (market cap $39.02B). The key difference: Yum! Brands, Inc. is far larger — about 8× Crispr Therapeutics AG's market cap, and Yum! Brands, Inc. pays a 2.1% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Yum! Brands, Inc. for 132 Days on average.
| CRSP | YUM | |
|---|---|---|
Market Cap | $4.88B | $39.02B |
Volume | 2,861,747 | 2,597,636 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $168.16 |
52-Week Low | $44.34 | $135.77 |
Typical Hold Time | 77 Days | 132 Days |
Enterprise Value | $3.30B | $50.63B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
YUM stock trades at $145.15, up 3.42% today, with a bullish technical signal and strong support at $141. Revenue grew to $8.21B in 2025, with net income of $1.56B and a 25.4% net margin. The company recently sold Pizza Hut for $1.5B, focusing on KFC and Taco Bell, and declared a $0.75 dividend payable September 18, 2026.
Outlook is positive with a consensus price target of $170.44, though high debt and competitive pressures pose risks. Earnings beat expectations in two of the last three quarters, and cash flow from operations is robust at $2.01B, supporting shareholder returns amid a hold-heavy analyst rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
